Your browser doesn't support javascript.
loading
Intravaginal Tolterodine Formulation Intended for Overactive Bladder Treatment-Results of a Pharmacokinetic Phase I Pilot Study in Healthy, Postmenopausal Women.
Donath, Frank; Hoffmann, Larissa; Todorova-Sanjari, Marina; Wedemeyer, Ralph-Steven; Warnke, André; Nickisch, Klaus.
Affiliation
  • Donath F; SocraTec R&D GmbH, Oberursel/Erfurt, Germany.
  • Hoffmann L; Evestra GmbH, Berlin, Germany.
  • Todorova-Sanjari M; SocraTec R&D GmbH, Oberursel/Erfurt, Germany.
  • Wedemeyer RS; SocraTec R&D GmbH, Oberursel/Erfurt, Germany.
  • Warnke A; SocraMetrics GmbH, Erfurt, Germany.
  • Nickisch K; SocraTec R&D GmbH, Oberursel/Erfurt, Germany.
Clin Pharmacol Drug Dev ; 11(1): 80-90, 2022 01.
Article in En | MEDLINE | ID: mdl-34101369
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder, Overactive / Tolterodine Tartrate Limits: Female / Humans Language: En Journal: Clin Pharmacol Drug Dev Year: 2022 Type: Article Affiliation country: Germany
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Urinary Bladder, Overactive / Tolterodine Tartrate Limits: Female / Humans Language: En Journal: Clin Pharmacol Drug Dev Year: 2022 Type: Article Affiliation country: Germany